<SEC-DOCUMENT>0001193125-23-130994.txt : 20230502
<SEC-HEADER>0001193125-23-130994.hdr.sgml : 20230502
<ACCEPTANCE-DATETIME>20230501212926
ACCESSION NUMBER:		0001193125-23-130994
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20230501
FILED AS OF DATE:		20230502
DATE AS OF CHANGE:		20230501

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			IMMUTEP Ltd
		CENTRAL INDEX KEY:			0001506184
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			C3
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-35428
		FILM NUMBER:		23876337

	BUSINESS ADDRESS:	
		STREET 1:		LEVEL 12, 95 PITT STREET
		CITY:			SYDNEY, NEW SOUTH WALES
		STATE:			C3
		ZIP:			2000
		BUSINESS PHONE:		612 9276 1224

	MAIL ADDRESS:	
		STREET 1:		LEVEL 12, 95 PITT STREET
		CITY:			SYDNEY, NEW SOUTH WALES
		STATE:			C3
		ZIP:			2000

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Prima BioMed Ltd
		DATE OF NAME CHANGE:	20101119
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>d493768d6k.htm
<DESCRIPTION>6-K
<TEXT>
<HTML><HEAD>
<TITLE>6-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM 6-K
</B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>REPORT OF FOREIGN PRIVATE ISSUER </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>PURSUANT TO RULE 13a-16 OR 15d-16 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>UNDER THE SECURITIES EXCHANGE ACT OF 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Dated May&nbsp;1, 2023 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Commission File Number 001-35428 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>IMMUTEP
LIMITED </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Exact Name as Specified in its Charter) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>N/A </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Translation of
Registrant&#146;s Name) </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Level 33, Australia Square </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>264 George Street, Sydney </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NSW 2000, Australia </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address of principal executive office) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether
the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Form
20-F&nbsp;&nbsp;&#9746;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Form 40-F&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the
registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the registrant
is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether by furnishing the
information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule&nbsp;12g3-2(b) under the Securities Exchange Act of 1934. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Yes&nbsp;&nbsp;&#9744;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;&nbsp;&#9746; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If &#147;Yes&#148; is marked, indicated below the file number assigned to the registrant in connection with Rule 12g3-2(b): Not applicable. </P>
<P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT INDEX </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="5%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="94%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Exhibit</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Description&nbsp;of&nbsp;Exhibit</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">99.1</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><A HREF="d493768dex991.htm">Immutep Receives Approval to Initiate INSIGHT-005 Trial Evaluating Eftilagimod Alpha and Anti-PD-L1 Therapy BAVENCIO
<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> </A></P></TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned, thereunto duly authorized. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dated: May&nbsp;1, 2023 </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">IMMUTEP LIMITED</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Marc Voigt</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Marc Voigt</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Chief Executive Officer</TD></TR>
</TABLE></DIV>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d493768dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g493768dsp1.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>ASX/Media Release </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Immutep Receives Approval to Initiate <FONT STYLE="white-space:nowrap">INSIGHT-005</FONT> Trial Evaluating </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Eftilagimod Alpha and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Anti-PD-L1</FONT></FONT> Therapy BAVENCIO<SUP
STYLE="font-size:75%; vertical-align:top">&reg;</SUP> </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Investigator-initiated study jointly funded with Merck KGaA, Darmstadt, Germany, will evaluate dual
immuno-oncology (IO) combination of eftilagimod alpha and BAVENCIO<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> in metastatic urothelial cancer </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Trial builds on strategy to cost-efficiently increase target indications for
<FONT STYLE="white-space:nowrap">IO-IO</FONT> combination approaches utilizing eftilagimod alpha in areas of high unmet need </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>SYDNEY,
AUSTRALIA &#150; 1</B><B></B><B>&nbsp;May </B><B>2023 &#150;</B> <U>Immutep Limited</U> (ASX: IMM; NASDAQ: IMMP), a clinical-stage biotechnology company developing novel <FONT STYLE="white-space:nowrap">LAG-3</FONT> immunotherapies for cancer and
autoimmune disease, today announces it has received regulatory approval from the Paul-Ehrlich-Institut (&#147;PEI&#148;), German Federal Institute for Vaccines and Biomedicines, to initiate <FONT STYLE="white-space:nowrap">INSIGHT-005,</FONT> an
investigator-initiated, open-label Phase I trial evaluating the safety and efficacy of eftilagimod alpha (&#147;efti&#148;) in combination with BAVENCIO<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> (avelumab) in up to 30 patients with
metastatic urothelial carcinoma. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Urothelial carcinoma is the most common type of bladder cancer. For 2023, it is estimated there will be 82,290 new cases
of bladder cancer and 16,710 deaths in the US alone.<SUP STYLE="font-size:75%; vertical-align:top">1</SUP> Patients not eligible for platinum-based chemotherapy or progressing during or after platinum-based chemotherapy represent an area of high
unmet need and will be enrolled in the trial. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;We are excited to get this important trial underway. In addition to possibly bringing a new
chemo-free treatment option to patients with advanced urothelial cancer, we hope to further build upon the encouraging clinical data we have seen to date combining efti and avelumab in other challenging cancers. Efti&#146;s unique activation of
antigen-presenting cells to fight cancer has shown a benefit with avelumab, and we believe this dual <FONT STYLE="white-space:nowrap">IO-IO</FONT> approach has broad potential to drive superior clinical outcomes across a variety of indications,
including bladder cancer where avelumab monotherapy has regulatory approval,&#148; said Immutep CEO, Marc Voigt. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">BAVENCIO<SUP
STYLE="font-size:75%; vertical-align:top">&reg;</SUP> is a checkpoint inhibitor owned by Merck KGaA, Darmstadt, Germany, that works by targeting and blocking a protein called <FONT STYLE="white-space:nowrap">PD-L1</FONT> on the surface of cancer
cells and certain immune cells, activating the cells to find and kill cancer cells. It is approved as a monotherapy for first-line maintenance treatment for adult patients with advanced urothelial carcinoma that has not progressed with first-line
platinum-containing chemotherapy in more than 60 countries around the world. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Efti, a soluble <FONT STYLE="white-space:nowrap">LAG-3</FONT> protein and
novel MHC Class&nbsp;II agonist, was previously evaluated in combination with BAVENCIO<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> in patients with advanced solid tumours <U>in the <FONT STYLE="white-space:nowrap">INSIGHT-004</FONT>
Phase I trial</U>. Encouragingly, deep and durable responses were achieved in patients with low or negative <FONT STYLE="white-space:nowrap">PD-L1</FONT> expression as well as immuno-oncology insensitive tumours. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g493768dsp1.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">INSIGHT-005</FONT> will be conducted by the Institute of Clinical Cancer
Research IKF at Krankenhaus Nordwest in Frankfurt as part of the investigator-initiated INSIGHT platform for studies investigating efti in different combination treatments and routes of administration. INSIGHT currently consists of 5 different arms
from stratums A to E <FONT STYLE="white-space:nowrap">(INSIGHT-005</FONT> is Stratum E). </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:75%; vertical-align:top">1</SUP></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">US National Cancer Institute: https://seer.cancer.gov/statfacts/html/urinb.html </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Eftilagimod Alpha (Efti) </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Efti is Immutep&#146;s
proprietary soluble <FONT STYLE="white-space:nowrap">LAG-3</FONT> protein and MHC Class&nbsp;II agonist that stimulates both innate and adaptive immunity for the treatment of cancer. As a <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">first-in-class</FONT></FONT> antigen presenting cell (APC) activator, efti binds to MHC (major histocompatibility complex) Class&nbsp;II molecules on APC leading to activation and proliferation of CD8+ cytotoxic T cells,
CD4+ helper T cells, dendritic cells, NK cells, and monocytes. It also upregulates the expression of key biological molecules like <FONT STYLE="white-space:nowrap">IFN-</FONT><FONT STYLE="FONT-FAMILY:SYMBOL">&#103;</FONT> and CXCL10 that further
boost the immune system&#146;s ability to fight cancer. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Efti is under evaluation for a variety of solid tumours including
<FONT STYLE="white-space:nowrap">non-small</FONT> cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), and metastatic breast cancer. Its favourable safety profile enables various combinations, including with <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-[L]1</FONT></FONT> immunotherapy and/or chemotherapy. Efti has received Fast Track Designation in 1st line HNSCC and in 1st line NSCLC from the United States Food and Drug
Administration (FDA). </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Immutep </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Immutep is a
clinical stage biotechnology company developing novel <FONT STYLE="white-space:nowrap">LAG-3</FONT> immunotherapy for cancer and autoimmune disease. We are pioneers in the understanding and advancement of therapeutics related to Lymphocyte
Activation <FONT STYLE="white-space:nowrap">Gene-3</FONT> <FONT STYLE="white-space:nowrap">(LAG-3),</FONT> and our diversified product portfolio harnesses its unique ability to stimulate or suppress the immune response. Immutep is dedicated to
leveraging its expertise to bring innovative treatment options to patients in need and to maximise value for shareholders. For more information, please visit <U>www.immutep.com</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Australian Investors/Media: </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Catherine Strong,
Citadel-MAGNUS </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">+61 (0)406 759 268; <U>cstrong@citadelmagnus.com</U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>U.S. Investors/Media: </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Chris Basta, VP, Investor
Relations and Corporate Communications </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">+1 (631) 318 4000; <U>chris.basta@immutep.com</U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This announcement was authorised for release by the Board of Immutep Limited. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Immutep Limited</B>, Level&nbsp;33, Australia Square, 264 George Street, Sydney NSW 2000, Australia </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ABN: 90 009 237 889 </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g493768dsp1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g493768dsp1.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@",LJ_>8#Z\4$W'*V1D<CUS04.H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H #TH PM<U6>RC2"U0O=2@[0.WO4RE;8YZ\VM$<+F
M[O[O;,TS-GYN"2M87D^IR2]HUHS6TDW=E:RWJWI1(V($;G[X^E4F^Y493C:[
M.UT^\2^LXKB,G##D>E:IG?"2E$MKP.:H:32U%H&% !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0!5NM0M;)D6XN$B9N@8]: )U;<FY3D
M8R".] #Z "@ H * "@ H * "@ H * "@ H * $Z4 &: %H * "@ H * "@ [
M4 <#XLEFMM=CFC=D81_*1V]?Z5A(\_$.TC;\,W<$NF"1B@FR1(QP#FJB;4I)
MQ.=\2HMQJ+W%KAX0N&VMP#]*GJ88AI['0^#0XT4ENF\X^E:1-\,FEJ=&O JS
MJW%H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@#C_
M !3X2GUZ]@N8;E8]B[65\_I2>@)JVITME;_8K&* N6\M -Q[TWL*ZN6<XZTK
MH8;N:+A=!NQUXIW0KI;C0Y)ZBGH.\6*"<^U)D)L4G'<471=T)O/8BA-,ER70
M-QR>E/0IZ(-_2INA1=UJ.S]*87$!H>@Q>: $+$4 4M8NI;+1[JYAP)(XRRY&
M1F@#D_!?B/4=:U6>.[D4HD>X!5QWH [K/>@ S@4 &[I0 FXYQC% "YQ0 A8C
MKB@ +8^GK0!BZ_HHU6V4HP6>/E2>A]JF2N85J49[G'ZA;W<*Q0"REAV#YBO.
MXUBTT<;C*&B$TW0-0OI K1/%#G+%^,T),4(2F]3T.RM([*T2WC^ZHK:*/2C%
M15BR!@50TK"T#"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H XOQ7JM[8ZG'%;3M&GE@D ]\G_"LINS..M4<'8WX[F4>'Q<[LR"$MD^
MN*T;]TTN^6YQ,.J:YJ<@CAN9"^,D*<5SJ3;.25:3=D/EN]>TAT>::4*?[YR*
MJ5T2JDX[DPU;7=8)%KN0# .SBH3;+5251D#:CK>D3J+F649/ <Y#5:DT2Y2I
MRU.ZTN_&HZ?'<+P3P1Z&M8NYZ,9)QN<7J6M:I)JLEK!<.N)-BA3BL92=SAJ5
M'>R&3#Q'9Q&>22?:.^XFDKK4$Y)7'+XCUB^1;6WSYF.J_>-5S,GV\I:#+B7Q
M#IZB:6:=5[DMD4:H?/.+.G\-ZT^J0.DV/.B.#CN/6M8RN=5.?,<UXXUS4M,U
MJ.*TNGBC\H-@'OD_X53.@[;1Y7GTBTED8L[Q@DF@#AO&NN:GINNF&TO)(H_+
M!V@]Z .IU.1I?!4LCDEGM0Q)]2!0!Y;H9U<7+G1Q,9MN&\OTH [#P^?%G]L0
M?VBLXM_X]_2@#IO$>NQ:!IQG9=\SG$:>IH X&&\\5^(I7FM9IA&/[C;0/:@!
MUKXCU[P]?K!J32.G!993DX]0: /0;[4?^*>GU&T?!\DR(<9H \SM=6\3ZW<%
M+6[G>11DA'V@4 337?BS0SYUQ+<A#W=BPH [;PMXG378&CD4)=1C++V(]:;"
MQT>Q3U&?K2L+E0*H7I4\H**0X56Q0M @H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M(<@]N* /*?"$C6WC&WC1N"SQ'Z8)_I2L.Y[#3$% !0 =* "@ H * "@ H *
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M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
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MZ8CW!DX(.: .KC^&=DLF7O)2G=0H&?KQ0!UVG:9:Z5:+;6L02,>G>@"Y0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0!
M52XW7TEOL("(K[O]XM_\30!%?:B+)XQLW[CEL?PJ.IH ?<7+1-%%$@DDDS@9
MQP.] $T4C>63-L5A_=;(_.@"K>7LEK-$-D921U4$O@\]>,4 6Y7\J-G )V@F
M@"C+J8B6Q8QG%Q@MC^$8_P 2* )(]0634'M%&0J;M_;KTH ACUA&M[B0Q$-$
MY4+_ '@#P?QH GCORZ6;>61]HZC^[QF@!EQJ/DVUY*(BWV8$X_O4 .CU$2SV
M\2J09 VX=T(QQ^M $1U"X>.2>"W5H$W9RQ#-C@X&* '7%Y-'##+! CI*RJ,O
MMQDX]* ))+T0RV\<ZJAE5B3NX!&/\: (WU-?LUS/&J,L,@CR7X.<<_K0 -?R
M1Z;/=%8G\I"P$<F>@Z4 /M;UI;IK=T3[H8%'W?G0 D>HA[]K?9@ '8W]XC&1
M^M $,^J/!)+^[C\J)@"-_P QSZ"@":;4/(F>.2/#=8\'[] $&OL3X:OBPVGR
M&)'IQ0!POPV_Y#=S_P!<OZT >HT % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0!0>SF%\US%,$WHJE2N>A/^- "2
M:9'-/)+-ERRA<= !WH :--=(K=4F(EMQM$A&210!+!9;$D69O,\R0R'M@X _
MI0 EU927)4>8%0$'[N2,>E %AXS)"Z'(W+CZ4 5CIZLL"MDB*(Q8]<[>?TH
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MVGSVI?;YJ%,XSC- &%X<\'IX?O'N$NVE+KM(*XH ZB@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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MVM._Y^X_SHYT'M8A_;6G?\_<?YT<Z#VL0_MK3O\ G[C_ #HYT'M8A_;6G?\
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M*P^KS#_A%-6_YX+_ -]#_&CE8?5YA_PBFK?\\%_[Z'^-'*P^KS#_ (135O\
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M]#_&CE8?5YA_PBFK?\\%_P"^A_C1RL/J\P_X135O^>"_]]#_ !HY6'U>8?\
M"*:M_P \%_[Z'^-'*P^KS#_A%-6_YX+_ -]#_&CE8?5YA_PBFK?\\%_[Z'^-
M'*P^KS#_ (135O\ G@O_ 'T/\:.5A]7F'_"*:M_SP7_OH?XT<K#ZO,/^$4U;
M_G@O_?0_QHY6'U>8?\(IJW_/!?\ OH?XT<K#ZO,/^$4U;_G@O_?0_P :.5A]
M7F'_  BFK?\ /!?^^A_C1RL/J\P_X135O^>"_P#?0_QHY6'U>8?\(IJW_/!?
M^^A_C1RL/J\P_P"$4U;_ )X+_P!]#_&CE8?5YA_PBFK?\\%_[Z'^-'*P^KS#
M_A%-6_YX+_WT/\:.5A]7F'_"*:M_SP7_ +Z'^-'*P^KS#_A%-6_YX+_WT/\
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M#_A%-6_YX+_WT/\ &CE8?5YA_P (IJW_ #P7_OH?XT<K#ZO,/^$4U;_G@O\
MWT/\:.5A]7F'_"*:M_SP7_OH?XT<K#ZO,/\ A%-6_P">"_\ ?0_QHY6'U>8?
M\(IJW_/!?^^A_C1RL/J\P_X135O^>"_]]#_&CE8?5YA_PBFK?\\%_P"^A_C1
MRL/J\P_X135O^>"_]]#_ !HY6'U>8?\ "*:M_P \%_[Z'^-'*P^KS#_A%-6_
MYX+_ -]#_&CE8?5YA_PBFK?\\%_[Z'^-'*P^KS#_ (135O\ G@O_ 'T/\:.5
MA]7F'_"*:M_SP7_OH?XT<K#ZO,/^$4U;_G@O_?0_QHY6'U>8?\(IJW_/!?\
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7+!<*+!<*+!<*+!<*+!<*+!<*+!<__]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
